SIA
UTHR icon

Stancorp Investment Advisers’s United Therapeutics UTHR Stock Holding History

Stancorp Investment Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$10K Hold
60
– – ﹤0.01% 457
2014
Q4 		$8K Buy
+60
New +$7.73K ﹤0.01% 460

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Stancorp Investment Advisers's UTHR Position: Q1 2015 in Review

Stancorp Investment Advisers held its United Therapeutics (UTHR) position steady in Q1 2015 at 60 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #457.

Stancorp Investment Advisers first reported a position in UTHR in Q4 2014 and has held it in 2 quarters since. 366 funds tracked by Wall St. Rank hold UTHR as of Q1 2015.

  • Stancorp Investment Advisers held 60 shares of United Therapeutics worth $10K as of Q1 2015.
  • Stancorp Investment Advisers left its United Therapeutics share count unchanged in Q1 2015.
  • United Therapeutics made up ﹤0.01% of Stancorp Investment Advisers's portfolio in Q1 2015, its #457 holding.
  • Stancorp Investment Advisers first reported a position in United Therapeutics in Q4 2014 and has held it in 2 quarters since.
  • 366 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.